GRI Bio (GRI) Competitors $1.99 +0.02 (+1.02%) As of 07/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRI vs. IXHL, RLYB, ASBP, VYNE, PASG, GELS, EDSA, BIVI, LPCN, and DRRXShould you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include Incannex Healthcare (IXHL), Rallybio (RLYB), Aspire Biopharma (ASBP), VYNE Therapeutics (VYNE), Passage Bio (PASG), Gelteq (GELS), Edesa Biotech (EDSA), BioVie (BIVI), Lipocine (LPCN), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry. GRI Bio vs. Its Competitors Incannex Healthcare Rallybio Aspire Biopharma VYNE Therapeutics Passage Bio Gelteq Edesa Biotech BioVie Lipocine DURECT GRI Bio (NASDAQ:GRI) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings. Do insiders & institutionals have more ownership in GRI or IXHL? 34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 0.1% of GRI Bio shares are owned by insiders. Comparatively, 15.5% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts prefer GRI or IXHL? GRI Bio currently has a consensus target price of $22.00, suggesting a potential upside of 1,005.53%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Incannex Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Incannex Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation and earnings, GRI or IXHL? GRI Bio has higher earnings, but lower revenue than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGRI BioN/AN/A-$8.21M-$11.56-0.17Incannex Healthcare$10K3,090.15-$18.46M-$1.21-0.87 Does the media refer more to GRI or IXHL? In the previous week, Incannex Healthcare had 4 more articles in the media than GRI Bio. MarketBeat recorded 7 mentions for Incannex Healthcare and 3 mentions for GRI Bio. GRI Bio's average media sentiment score of 0.63 beat Incannex Healthcare's score of 0.37 indicating that GRI Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRI Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incannex Healthcare 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is GRI or IXHL more profitable? GRI Bio's return on equity of -275.15% beat Incannex Healthcare's return on equity.Company Net Margins Return on Equity Return on Assets GRI BioN/A -275.15% -168.22% Incannex Healthcare N/A -342.92%-148.64% Which has more risk and volatility, GRI or IXHL? GRI Bio has a beta of -1.62, suggesting that its share price is 262% less volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 7.47, suggesting that its share price is 647% more volatile than the S&P 500. SummaryGRI Bio beats Incannex Healthcare on 8 of the 14 factors compared between the two stocks. Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRI vs. The Competition Export to ExcelMetricGRI BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.92M$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-0.1721.1828.1020.05Price / SalesN/A288.50432.4490.07Price / CashN/A42.7636.2258.56Price / Book0.268.378.665.87Net Income-$8.21M-$55.19M$3.25B$258.55M7 Day Performance9.34%5.88%4.23%3.74%1 Month Performance55.47%17.33%10.52%11.75%1 Year Performance-90.71%4.42%34.41%18.03% GRI Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRIGRI Bio2.9111 of 5 stars$1.99+1.0%$22.00+1,005.5%-90.8%$4.92MN/A-0.171IXHLIncannex Healthcare0.7438 of 5 stars$0.82+34.4%N/A-51.4%$17.95M$10K-0.683News CoverageGap DownHigh Trading VolumeRLYBRallybio2.872 of 5 stars$0.46+7.5%$10.00+2,063.1%-62.5%$17.89M$640K-0.4240Positive NewsASBPAspire BiopharmaN/A$0.41+14.1%N/AN/A$17.73MN/A0.00N/ANews CoverageAnalyst DowngradeGap DownVYNEVYNE Therapeutics2.9385 of 5 stars$1.21+4.3%$6.25+416.5%-30.5%$17.64M$500K-1.2230High Trading VolumePASGPassage Bio3.3868 of 5 stars$5.27-5.2%$150.00+2,746.3%-57.7%$17.35MN/A-0.26130News CoveragePositive NewsInsider TradeGap UpHigh Trading VolumeGELSGelteqN/A$1.83+0.5%N/AN/A$17.18M$100K0.00N/AGap UpEDSAEdesa Biotech2.3532 of 5 stars$2.41+0.4%$5.00+107.5%-53.2%$16.85MN/A-1.5220Positive NewsBIVIBioVie0.7623 of 5 stars$7.31-18.7%N/A+69.0%$16.73MN/A-0.0910News CoverageLPCNLipocine2.8716 of 5 stars$3.17+1.6%$9.00+183.9%-40.9%$16.67M$11.20M-3.1110DRRXDURECT1.1933 of 5 stars$0.57+5.5%N/A-65.6%$16.62M$2.03M-3.7780Positive NewsGap Down Related Companies and Tools Related Companies IXHL Alternatives RLYB Alternatives ASBP Alternatives VYNE Alternatives PASG Alternatives GELS Alternatives EDSA Alternatives BIVI Alternatives LPCN Alternatives DRRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRI) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRI Stock Alerts